消化

IF 1.3 Q4 NEUROSCIENCES

Progress in Neurology and Psychiatry Pub Date : 2021-09-17 DOI:10.1002/pnp.252

ZáNean D. McClain, Erin Snapp, Daniel Tindall, Jill Anderson

{"title":"消化","authors":"ZáNean D. McClain, Erin Snapp, Daniel Tindall, Jill Anderson","doi":"10.1002/pnp.252","DOIUrl":null,"url":null,"abstract":"Perampanel (Fycompa), an AMPAtype glutamate receptor antagonist, developed by Eisai has been launched as the first in a new class of treatment for uncontrolled partial epilepsy. It is indicated as an adjunctive treatment for partial onset seizures, with or without secondarily generalised seizures, in people with epilepsy aged 12 years and older.","PeriodicalId":43913,"journal":{"name":"Progress in Neurology and Psychiatry","volume":"16 1","pages":""},"PeriodicalIF":1.3000,"publicationDate":"2021-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/pnp.252","citationCount":"0","resultStr":"{\"title\":\"Digest\",\"authors\":\"ZáNean D. McClain, Erin Snapp, Daniel Tindall, Jill Anderson\",\"doi\":\"10.1002/pnp.252\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Perampanel (Fycompa), an AMPAtype glutamate receptor antagonist, developed by Eisai has been launched as the first in a new class of treatment for uncontrolled partial epilepsy. It is indicated as an adjunctive treatment for partial onset seizures, with or without secondarily generalised seizures, in people with epilepsy aged 12 years and older.\",\"PeriodicalId\":43913,\"journal\":{\"name\":\"Progress in Neurology and Psychiatry\",\"volume\":\"16 1\",\"pages\":\"\"},\"PeriodicalIF\":1.3000,\"publicationDate\":\"2021-09-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1002/pnp.252\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Progress in Neurology and Psychiatry\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1002/pnp.252\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"NEUROSCIENCES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Progress in Neurology and Psychiatry","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/pnp.252","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"NEUROSCIENCES","Score":null,"Total":0}

引用次数: 0

摘要

卫材开发的ampattype谷氨酸受体拮抗剂Perampanel (Fycompa)作为首个治疗不受控制部分性癫痫的新型药物上市。它适用于12岁及以上癫痫患者伴或不伴继发性全身性癫痫发作的部分性发作的辅助治疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Digest

Perampanel (Fycompa), an AMPAtype glutamate receptor antagonist, developed by Eisai has been launched as the first in a new class of treatment for uncontrolled partial epilepsy. It is indicated as an adjunctive treatment for partial onset seizures, with or without secondarily generalised seizures, in people with epilepsy aged 12 years and older.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Progress in Neurology and Psychiatry NEUROSCIENCES-

CiteScore

1.70

自引率

8.30%

发文量

期刊介绍： Progress in Neurology and Psychiatry is published nine times a year, and is a journal for specialists in secondary care, GPs with an interest in neurology and psychiatry, community psychiatric nurses and other specialist healthcare professionals. Articles cover management, news updates and opinion in all areas of neurology and psychiatry.